Comparable stake leader
Sermonix Pharmaceuticals, Inc.
SEC ownership of LeonaBio, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001620463.
Disclosed value leader
Sermonix Pharmaceuticals, Inc.
Comparable rows
48/50
Latest evidence
24 Aug 2026
- Public ticker
- LONA on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Sermonix Pharmaceuticals, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
48 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Sermonix Pharmaceuticals, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
24 Aug 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001620463
- Issuer location
- Bothell, WA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of LeonaBio, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Sermonix Pharmaceuticals,...
Disclosed value leader
Sermonix Pharmaceuticals,...
Comparable rows
48/50
Latest evidence
24 Aug 2026
13D/G
3/4/5
13F
Lead comparable stake: 37%
2 rows are not safely comparable across share classes.
13D/G row: Sermonix Pharmaceuticals, Inc.
Showing 1-8 of 50 holder rows.
Quick read
Sermonix Pharmaceuticals, Inc. leads the comparable SEC ownership view at 37%.
48 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Sermonix Pharmaceuticals, Inc.'s linked filing trail.
Comparable ownership
Top 5
Sermonix Pharmaceuticals, Inc.
37%
PERCEPTIVE ADVISORS LLC
20%
ACORN BIOVENTURES, L.P.
12%
ADAR1 Capital Management, LLC
7.7%
Steven Michael Oliveira
4.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Sermonix Pharmaceuticals, Inc. |
13D/G
|
37%
|
$52,382,867
5,502,402 shares
|
$0 | 24 Aug 2026 |
| PERCEPTIVE ADVISORS LLC |
13D/G
3/4/5
13F
Director, 10%+ Owner · Company
|
20%
|
$17,987,117
1,889,403 shares
|
+$286,371 | 22 Aug 2026 |
| ACORN BIOVENTURES, L.P. |
13D/G
Anders Hove
|
12%
|
$14,208,800
1,492,521 shares
|
$0 | 18 Aug 2026 |
| ADAR1 Capital Management, LLC |
13F
13D/G
Company
|
7.7%
from 13D/G
|
$7,141,549
777,100 shares
|
— | 30 Jun 2026 |
| Steven Michael Oliveira |
13D/G
Oliveira Steven Michael
|
4.1%
|
$69,324
161,218 shares
|
-$788,375 | 01 Oct 2025 |
| Baselake Partners, LP |
13D/G
|
1.9%
|
$573,723
75,789 shares
|
-$921,208 | 31 Dec 2025 |
| ACORN CAPITAL ADVISORS, LLC |
13F
Company
|
4.3%
|
$5,831,413
634,539 shares
|
— | 30 Jun 2026 |
| Commodore Capital LP |
13F
Company
|
3.1%
|
$4,267,818
464,398 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$99,418.
Buys
$0
Insiders: 0
Sells
$99,418
Insiders: 5
Net
-$99,418
Shares: -16,748
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 16,748
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 16,748 | $0 | $99,418 | -$99,418 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 23 reporting-owner rows connected to LeonaBio, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
23
Largest Forms 3/4/5 holder
PERCEPTIVE ADVISORS LLC
Net 12M change
-$99,418
Latest report
24 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | Director, 10%+ Owner | $17,718,931 | Mixed | 23 Jun 2026 | ||
| Mark James Litton | PRESIDENT and CEO, Director | $445,121 | -$45,479 | -9.3% | Mixed | 09 Apr 2026 |
| Hans Moebius | Chief Medical Officer | $266,213 | Mixed | 04 Jan 2024 | ||
| Kelly A. Romano | Director | $194,951 | Filing P/S | 23 Jun 2026 | ||
| Kevin Church | Chief Scientific Officer | $168,112 | -$13,325 | -7.3% | Mixed | 09 Apr 2026 |
| Mark Worthington | GENERAL COUNSEL and CCO | $130,855 | -$13,158 | -9.1% | Mixed | 09 Apr 2026 |
| Javier San Martin | Chief Medical Officer | $126,995 | -$20,547 | -14% | Mixed | 09 Apr 2026 |
| Robert Renninger | Chief Financial Officer | $107,033 | -$6,909 | -6.1% | Mixed | 09 Apr 2026 |
| Andrew Gengos | CFO and Chief Business Officer | $55,203 | Filing P/S | 03 Sep 2024 | ||
| Rachel Lenington | COO and CDO | $11,812 | Filing P/S | 03 Sep 2024 | ||
| Glenna Mileson | Chief Financial Officer | Mixed | 19 Jan 2023 | |||
| Tadataka Yamada | Director | Mixed | 28 May 2021 | |||
| David J. Portman | 10%+ Owner | Mixed | 24 Aug 2026 | |||
| Grant Pickering | Director | Mixed | 23 Jun 2026 | |||
| Joseph Edelman | Director, 10%+ Owner | Mixed | 23 Jun 2026 | |||
| Michael A. Panzara | Director | Mixed | 23 Jun 2026 | |||
| Barbara Kosacz | Director | Mixed | 23 Jun 2026 | |||
| John M. Fluke Jr. | Director | Mixed | 09 Apr 2026 | |||
| James A. Johnson | Director | Mixed | 23 Jun 2026 | |||
| Peter B. Silverman | Director | Mixed | 23 Jun 2026 |
Recent insider transactions for LeonaBio, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Perceptive Advisors Llc | LONA | Stock Option (Right to Buy) | Award | 28,000 | 28,000 | 23 Jun 2026 | See footnote | |||
| PERCEPTIVE ADVISORS LLC | LONA | Stock Option (Right to Buy) | Award | 28,000 | 28,000 | 23 Jun 2026 | See footnote | |||
| Perceptive Advisors Llc | LONA | Stock Option (Right to Buy) | Award | 28,000 | 28,000 | 23 Jun 2026 | See footnote | |||
| Fred P. Callori | LONA | Stock Option (Right to Buy) | Award | 2,333 | 2,333 | 23 Jun 2026 | Direct | |||
| Natalie C. Holles | LONA | Stock Option (Right to Buy) | Award | 2,333 | 2,333 | 23 Jun 2026 | Direct | |||
| Peter B. Silverman | LONA | Stock Option (Right to Buy) | Award | 2,333 | 2,333 | 23 Jun 2026 | Direct | |||
| Michael A. Panzara | LONA | Stock Option (Right to Buy) | Award | 28,000 | 28,000 | 23 Jun 2026 | Direct | |||
| Kelly A. Romano | LONA | Stock Option (Right to Buy) | Award | 28,000 | 28,000 | 23 Jun 2026 | Direct | |||
| Joseph Edelman | LONA | Stock Option (Right to Buy) | Award | 28,000 | 28,000 | 23 Jun 2026 | Direct | |||
| James A. Johnson | LONA | Stock Option (Right to Buy) | Award | 28,000 | 28,000 | 23 Jun 2026 | Direct | |||
| Barbara Kosacz | LONA | Stock Option (Right to Buy) | Award | 28,000 | 28,000 | 23 Jun 2026 | Direct | |||
| Grant Pickering | LONA | Stock Option (Right to Buy) | Award | 28,000 | 28,000 | 23 Jun 2026 | Direct | |||
| Natalie C. Holles | LONA | Stock Option (Right to Buy) | Award | 56,000 | 56,000 | 05 May 2026 | Direct | |||
| Peter B. Silverman | LONA | Stock Option (Right to Buy) | Award | 56,000 | 56,000 | 05 May 2026 | Direct | |||
| Fred P. Callori | LONA | Stock Option (Right to Buy) | Award | 56,000 | 56,000 | 05 May 2026 | Direct | |||
| Perceptive Advisors Llc | LONA | Stock Option (Right to Buy) | Award | 28,000 | 28,000 | 09 Apr 2026 | See footnote | |||
| PERCEPTIVE ADVISORS LLC | LONA | Stock Option (Right to Buy) | Award | 28,000 | 28,000 | 09 Apr 2026 | See footnote | |||
| Perceptive Advisors Llc | LONA | Stock Option (Right to Buy) | Award | 28,000 | 28,000 | 09 Apr 2026 | See footnote | |||
| Michael A. Panzara | LONA | Stock Option (Right to Buy) | Award | 28,000 | 28,000 | 09 Apr 2026 | Direct | |||
| Kevin Church | LONA | Stock Option (Right to Buy) | Award | 300,000 | 300,000 | 09 Apr 2026 | Direct | |||
| Barbara Kosacz | LONA | Stock Option (Right to Buy) | Award | 28,000 | 28,000 | 09 Apr 2026 | Direct | |||
| Grant Pickering | LONA | Stock Option (Right to Buy) | Award | 28,000 | 28,000 | 09 Apr 2026 | Direct | |||
| Kelly A. Romano | LONA | Stock Option (Right to Buy) | Award | 28,000 | 28,000 | 09 Apr 2026 | Direct | |||
| James A. Johnson | LONA | Stock Option (Right to Buy) | Award | 28,000 | 28,000 | 09 Apr 2026 | Direct | |||
| Joseph Edelman | LONA | Stock Option (Right to Buy) | Award | 28,000 | 28,000 | 09 Apr 2026 | Direct | |||
| Javier San Martin | LONA | Stock Option (Right to Buy) | Award | 350,000 | 350,000 | 09 Apr 2026 | Direct | |||
| John M. Fluke Jr. | LONA | Stock Option (Right to Buy) | Award | 28,000 | 28,000 | 09 Apr 2026 | Direct | |||
| Mark Worthington | LONA | Stock Option (Right to Buy) | Award | 300,000 | 300,000 | 09 Apr 2026 | Direct | |||
| Robert Renninger | LONA | Stock Option (Right to Buy) | Award | 300,000 | 300,000 | 09 Apr 2026 | Direct | |||
| Mark James Litton | LONA | Stock Option (Right to Buy) | Award | 750,000 | 750,000 | 09 Apr 2026 | Direct | |||
| Mark James Litton | LONA | Common Stock | Sale | -8.17% | $27,688 | $5.37 | -5,156 | 57,926 | 04 Mar 2026 | Direct |
| Robert Renninger | LONA | Common Stock | Sale | -5.41% | $4,865 | $5.37 | -906 | 15,851 | 04 Mar 2026 | Direct |
| Mark Worthington | LONA | Common Stock | Sale | -6.74% | $7,131 | $5.37 | -1,328 | 18,376 | 04 Mar 2026 | Direct |
| Kevin Church | LONA | Common Stock | Sale | -5.12% | $7,298 | $5.37 | -1,359 | 25,178 | 04 Mar 2026 | Direct |
| Javier San Martin | LONA | Common Stock | Sale | -9.77% | $9,236 | $5.37 | -1,720 | 15,887 | 04 Mar 2026 | Direct |
| Mark James Litton | LONA | Common Stock | Options Exercise | 54.5% | 22,254 | 63,082 | 03 Mar 2026 | Direct | ||
| Mark James Litton | LONA | Restricted Stock Units | Options Exercise | -100% | -22,254 | 0 | 03 Mar 2026 | Direct | ||
| Robert Renninger | LONA | Common Stock | Options Exercise | 30.3% | 3,900 | 16,757 | 03 Mar 2026 | Direct | ||
| Robert Renninger | LONA | Restricted Stock Units | Options Exercise | -100% | -3,900 | 0 | 03 Mar 2026 | Direct | ||
| Mark Worthington | LONA | Common Stock | Options Exercise | 41% | 5,726 | 19,704 | 03 Mar 2026 | Direct | ||
| Mark Worthington | LONA | Restricted Stock Units | Options Exercise | -100% | -5,726 | 0 | 03 Mar 2026 | Direct | ||
| Kevin Church | LONA | Common Stock | Options Exercise | 28.3% | 5,856 | 26,537 | 03 Mar 2026 | Direct | ||
| Kevin Church | LONA | Restricted Stock Units | Options Exercise | -100% | -5,856 | 0 | 03 Mar 2026 | Direct | ||
| Javier San Martin | LONA | Common Stock | Options Exercise | 72.8% | 7,418 | 17,607 | 03 Mar 2026 | Direct | ||
| Javier San Martin | LONA | Restricted Stock Units | Options Exercise | -100% | -7,418 | 0 | 03 Mar 2026 | Direct | ||
| Javier San Martin | ATHA | Common Stock | Sale | -13.9% | $11,311 | $6.88 | -1,644 | 10,189 | 02 Jan 2026 | Direct |
| Mark James Litton | ATHA | Common Stock | Sale | -5.96% | $17,792 | $6.88 | -2,586 | 40,828 | 02 Jan 2026 | Direct |
| Robert Renninger | ATHA | Common Stock | Sale | -2.26% | $2,043 | $6.88 | -297 | 12,857 | 02 Jan 2026 | Direct |
| Kevin Church | ATHA | Common Stock | Sale | -4.06% | $6,027 | $6.88 | -876 | 20,681 | 02 Jan 2026 | Direct |
| Mark Worthington | ATHA | Common Stock | Sale | -5.9% | $6,027 | $6.88 | -876 | 13,978 | 02 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.